3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Neoplasms
4
Breast Neoplasms
4
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Tongue Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Endometrial Stromal
1
Sarcoma
1
Rhabdomyosarcoma
1
Pleural Effusion, Malignant
1
Neoplasms, Plasma Cell
1
Melanoma
1
Lymphangioleiomyomatosis
1
Lung Neoplasms
1
Liver Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Fibrosarcoma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colonic Neoplasms
1
Choriocarcinoma
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
87
Paclitaxel
77
Bevacizumab
38
Topotecan
23
liposomal doxorubicin
22
Gemcitabine
22
Taxes
21
Cisplatin
17
Drug Therapy
14
Docetaxel
14
Cyclophosphamide
14
pembrolizumab
13
Immunoglobulin G
12
Disulfides
12
veliparib
8
rucaparib
8
mirvetuximab soravtansine
8
niraparib
7
Albumin-Bound Paclitaxel
7
sargramostim
6
Filgrastim
6
Erlotinib Hydrochloride
6
Doxorubicin
6
pazopanib
5
Granulocyte-Macrophage Colony-Stimulating Factor
5
Chemotherapy, Adjuvant
5
CP protocol
5
trebananib
4
temsirolimus
4
olaparib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Fallopian Tube Neoplasms
×
saracatinib
×
Clear all
NCT01196741
2015-05-05
SaPPrOC
University College, London
Phase 2/3
Completed
107 enrolled
17 charts